Biotechnology

Savara

Savara released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.15 (forecast USD -0.135)

Savara released FY2025 Q4 earnings on March 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1341 (forecast USD -0.1162)

Savara released FY2025 Annual Earnings on March 13 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.5343 (forecast USD -0.5162)

Savara Inc. signs exclusive distribution agreement and faces financial challenges

Savara Inc. Publishes MOLBREEVI Progress Presentation for aPAP

Savara Inc. Submits BLA for MOLBREEVI to FDA

HC Wainwright Raises Savara Inc. Earnings Per Share Forecast and Maintains 'Buy' Rating

Analyst Maintains Buy Rating on Savara Shares

Savara Inc. Resubmits MOLBREEVI’s Biologics License Application

Savara Inc. Plans to Resubmit BLA in December 2025

Savara Inc.'s MOLBREEVI Obtains European Patent

Savara director exercises options and sells shares

Savara Inc. Publishes Progress Presentation on New Therapy

Savara and PARI Obtain Patent Protection for MOLBREEVI and eFlow Combination Therapy

Savara Inc. to Attend Piper Sandler and Evercore ISI Annual Healthcare Conferences

Oppenheimer Analyst Reiterates Buy Rating on Savara

Analyst Maintains Savara Buy Rating With $11.00 Price Target

Savara released FY2025 9 Months Earnings on November 12, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.4002

Savara released FY2025 Q3 earnings on November 12, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.1365 (forecast USD -0.1325)

Savara Inc. Advances Development of Novel Therapy MOLBREEVI for Rare Respiratory Diseases

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SVRA

LABU

LABD

SBIO

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

StockTitan

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bear 3X

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Savara (SVRA) with a price target of $9.00. The overall analyst consensus for Savara is a Strong Buy, with an average price target of $11.00. Brisebois has a 40.11% success rate on his stock recommendations.

Tip Ranks

Praxis Precision Medicines

Opus Genetics

LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)

In Laval, Quebec on May 6, 2026, Savaria Corporation, a major player in the accessibility sector, shared its performance for the first quarter of 2026. Savaria, trading under the ticker symbol SIS on the TSX, reported strong financial figures for this period.

Unusual Whales

Savaria Improves Earnings per Share by 82% Over Q1 2025

In a recent report, Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Savaria (SIS) with a price target of C$35.00. The analyst consensus for Savaria is a Strong Buy, with an average price target of C$34.20. Keywood focuses on the Healthcare sector and has an average return of -1.6% with a 50.73% success rate on his stock recommendations.

Stifel Financial

NervGen Pharma

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Savaria (SIS) Receives a Buy from Stifel Nicolaus

KVYO

GYRE

The US market has seen a 30% rise over the past year, with earnings expected to grow by 16% annually. Key high-growth tech stocks include Gyre Therapeutics, Savara, and Klaviyo, each demonstrating strong revenue and earnings growth. Gyre focuses on organ fibrosis treatments, Savara on rare respiratory diseases, and Klaviyo offers a cloud-based SaaS platform. These companies are positioned for robust growth amid a competitive landscape, with significant innovations and strategic maneuvers enhancing their market presence.

Simplywall

Klaviyo

Gyre Therapeutics

Marker Therapeutics

Palantir Tech

Reddit

Fabrinet

Sandisk

Gorilla Tech

Zscaler

Circle

Duos Tech

Shopify 

Sandisk - WI

GORILLA TECHNOLOGY GROUP INC C/WTS (TO PUR COM)

US High Growth Tech Stocks To Watch

Savara (SVRA) has faced recent share price weakness, declining 3.9% in the latest session and 17.9% over the past 90 days, despite a 51.1% total return over the past year. The company, valued at approximately $1.3 billion, reports no revenue and a net loss of $118.8 million. Its price-to-book (P/B) ratio stands at 6.2x, which is attractive compared to peers but high relative to the broader biotech sector average of 2.5x. Investors are weighing the potential for future growth against ongoing losses and execution risks.

Assessing Savara (SVRA) Valuation After Recent Share Price Weakness And Ongoing Losses

Savara(SVRA.US)

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)

Savaria Improves Earnings per Share by 82% Over Q1 2025

Savaria (SIS) Receives a Buy from Stifel Nicolaus

US High Growth Tech Stocks To Watch

Assessing Savara (SVRA) Valuation After Recent Share Price Weakness And Ongoing Losses